27596135|t|Circulating progenitor cells and coronary microvascular dysfunction: Results from the NHLBI -sponsored Women's Ischemia Syndrome Evaluation - Coronary Vascular Dysfunction Study (WISE-CVD)
27596135|a|Ischemia stimulates a reparative response resulting in mobilization of circulating progenitor cells (CPCs). We hypothesized that women with chronic myocardial ischemia from coronary microvascular disease (CMD) will mobilize CPCs. In 123 women with ischemic symptoms and signs but no obstructive coronary artery disease (CAD) enrolled in the Women's Ischemia Syndrome Evaluation - Coronary Vascular Dysfunction Study (WISE-CVD), we measured coronary flow reserve (CFR) in response to intracoronary adenosine. Peripheral blood CPCs were measured using flow cytometry for expression of CD34, CD133, CXCR4, and VEGFR2. Subjects were 53 ± 11 years, BMI 30 ± 8; 44% hypertensive, 11% diabetic, 23% hyperlipidemic and 7% smokers. Lower CFR correlated inversely with higher levels of hematopoietic -enriched CD34+ (r = -0.23, p = 0.011), CD34+ / CD133+ (r = -0.24, p = 0.008), and CD34+ / CXCR4+ (r = -0.19, p = 0.036) cells. In multivariable regression analyses, after adjusting for traditional cardiovascular risk factors, lower CFR remained significantly associated with elevated levels of CD34+ (β -0.18, p = 0.042), CD34+ / CD133+ (β -0.24, p = 0.036), and CD34+ / CXCR4+ (β -0.22, p = 0.050) cells. We found no association between CFR and CD34+ / VEGFR2+ cells. In women with non-obstructive CAD, impaired CFR is associated with higher levels of CPCs, suggesting that chronic myocardial ischemia from CMD stimulates CPC mobilization. The functional significance of elevated CPCs in these subjects requires further investigation as a potential biomarker and treatment target.
27596135	0	28	Circulating progenitor cells	T025	C3850017
27596135	33	67	coronary microvascular dysfunction	T047	C2827469
27596135	86	91	NHLBI	T093	C1955970
27596135	103	110	Women's	T098	C0043210
27596135	111	128	Ischemia Syndrome	T047	C0151744
27596135	129	139	Evaluation	T058	C0220825
27596135	142	171	Coronary Vascular Dysfunction	T047	C2827469
27596135	172	177	Study	T062	C2603343
27596135	179	187	WISE-CVD	T033	C0422739
27596135	189	197	Ischemia	T046	C0022116
27596135	198	208	stimulates	T033	C0243095
27596135	244	256	mobilization	T169	C0300926
27596135	260	288	circulating progenitor cells	T025	C3850017
27596135	260	288	circulating progenitor cells	T025	C3850017
27596135	290	294	CPCs	T025	C3850017
27596135	318	323	women	T098	C0043210
27596135	329	356	chronic myocardial ischemia	T047	C0264694
27596135	362	392	coronary microvascular disease	T047	C2827469
27596135	394	397	CMD	T047	C2827469
27596135	413	417	CPCs	T025	C3850017
27596135	437	445	ischemic	T169	C0475224
27596135	446	464	symptoms and signs	T184	C0037088
27596135	469	483	no obstructive	T169	C0205304
27596135	484	507	coronary artery disease	T047	C0010054
27596135	509	512	CAD	T047	C0010054
27596135	530	537	Women's	T098	C0043210
27596135	538	555	Ischemia Syndrome	T047	C0151744
27596135	556	566	Evaluation	T058	C0220825
27596135	569	598	Coronary Vascular Dysfunction	T047	C2827469
27596135	599	604	Study	T062	C2603343
27596135	606	614	WISE-CVD	T033	C0422739
27596135	620	650	measured coronary flow reserve	T060	C0199680
27596135	652	655	CFR	T060	C0199680
27596135	660	668	response	T032	C0871261
27596135	686	695	adenosine	T114,T121,T123	C0001443
27596135	697	713	Peripheral blood	T031	C0229664
27596135	714	718	CPCs	T025	C3850017
27596135	724	732	measured	T080	C0444706
27596135	739	753	flow cytometry	T059	C0016263
27596135	758	768	expression	T045	C1171362
27596135	772	776	CD34	T116,T129	C0054953
27596135	778	783	CD133	T116,T129	C0673028
27596135	785	790	CXCR4	T116,T192	C2352110
27596135	796	802	VEGFR2	T116,T126,T192	C3849882
27596135	804	812	Subjects	T098	C0080105
27596135	833	836	BMI	T201	C1305855
27596135	849	861	hypertensive	T047	C0020538
27596135	867	875	diabetic	T047	C0011847
27596135	881	895	hyperlipidemic	T047	C0020473
27596135	903	910	smokers	T033	C0337664
27596135	912	917	Lower	T052	C2003888
27596135	918	921	CFR	T060	C0199680
27596135	922	932	correlated	T080	C1707520
27596135	948	954	higher	T080	C0205250
27596135	955	961	levels	T080	C0441889
27596135	965	978	hematopoietic	T169	C0229601
27596135	989	994	CD34+	T116,T129	C0054953
27596135	1019	1024	CD34+	T116,T129	C0054953
27596135	1027	1033	CD133+	T116,T129	C0673028
27596135	1062	1067	CD34+	T116,T129	C0054953
27596135	1070	1076	CXCR4+	T116,T192	C2352110
27596135	1100	1105	cells	T025	C0007634
27596135	1110	1143	multivariable regression analyses	T170	C0034980
27596135	1177	1204	cardiovascular risk factors	T047	C0850624
27596135	1206	1211	lower	T052	C2003888
27596135	1212	1215	CFR	T060	C0199680
27596135	1239	1254	associated with	T080	C0332281
27596135	1255	1263	elevated	T080	C3163633
27596135	1264	1270	levels	T080	C0441889
27596135	1274	1279	CD34+	T116,T129	C0054953
27596135	1302	1307	CD34+	T116,T129	C0054953
27596135	1310	1316	CD133+	T116,T129	C0673028
27596135	1343	1348	CD34+	T116,T129	C0054953
27596135	1351	1357	CXCR4+	T116,T192	C2352110
27596135	1379	1384	cells	T025	C0007634
27596135	1418	1421	CFR	T060	C0199680
27596135	1426	1431	CD34+	T116,T129	C0054953
27596135	1434	1441	VEGFR2+	T116,T126,T192	C3849882
27596135	1442	1447	cells	T025	C0007634
27596135	1452	1457	women	T098	C0043210
27596135	1463	1478	non-obstructive	T169	C0205304
27596135	1479	1482	CAD	T047	C0010054
27596135	1493	1496	CFR	T060	C0199680
27596135	1500	1515	associated with	T080	C0332281
27596135	1516	1522	higher	T080	C0205250
27596135	1523	1529	levels	T080	C0441889
27596135	1533	1537	CPCs	T025	C3850017
27596135	1555	1582	chronic myocardial ischemia	T047	C0264694
27596135	1588	1591	CMD	T047	C2827469
27596135	1592	1602	stimulates	T033	C0243095
27596135	1603	1606	CPC	T025	C3850017
27596135	1607	1619	mobilization	T169	C0300926
27596135	1625	1635	functional	T169	C0205245
27596135	1636	1648	significance	T078	C0750502
27596135	1652	1660	elevated	T080	C3163633
27596135	1661	1665	CPCs	T025	C3850017
27596135	1675	1683	subjects	T098	C0080105
27596135	1701	1714	investigation	T058	C0220825
27596135	1720	1729	potential	T080	C3245505
27596135	1730	1739	biomarker	T201	C0005516
27596135	1744	1753	treatment	T061	C0087111
27596135	1754	1760	target	T169	C1521840